Evidence map›Paper›PMID 32192169›Full record

ArticleCancers2020

Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia.

Elise Aasebø, Frode S Berven, Sushma Bartaula-Brevik, Tomasz Stokowy, Randi Hovland, Marc Vaudel, Stein Ove Døskeland, Emmet McCormack, Tanveer S Batth, Jesper V Olsen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Special Issue "Personal Therapy for Blood Disorders".Journal of personalized medicine · 2023
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Elise AasebøDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.ORCID 0000-0002-6939-8059
Frode S BervenThe Proteomics Facility of the University of Bergen (PROBE), University of Bergen, 5009 Bergen, Norway.
Sushma Bartaula-BrevikDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Tomasz StokowyDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.ORCID 0000-0003-0017-8338
Randi HovlandDepartment for Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway.
Marc VaudelDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Stein Ove DøskelandThe Department of Biomedicine, University of Bergen, 5009 Bergen, Norway.
Emmet McCormackCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Tanveer S BatthNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, 2200 Copenhagen, Denmark.
Jesper V OlsenNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, 2200 Copenhagen, Denmark.
Øystein BruserudDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Frode SelheimThe Proteomics Facility of the University of Bergen (PROBE), University of Bergen, 5009 Bergen, Norway.
Maria Hernandez-ValladaresDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NOUniversity of Copenhagen · DK

Funding

Kreftforeningen 100933Norges Forskningsråd 245979/F50Novo Nordisk NNF14CC0001
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a hematological cancer that mainly affects the elderly. Although complete remission (CR) is achieved for the majority of the patients after induction and consolidation therapies, nearly two-thirds relapse within a short interval. Understanding biological factors that determine relapse has become of major clinical interest in AML. We utilized liquid chromatography tandem mass spectrometry (LC-MS/MS) to identify the protein changes and protein phosphorylation events associated with AML relapse in primary cells from 41 AML patients at time of diagnosis. Patients were defined as relapse-free if they had not relapsed within a five-year clinical follow-up after AML diagnosis. Relapse was associated with increased expression of RNA processing proteins and decreased expression of V-ATPase proteins. We also observed an increase in phosphorylation events catalyzed by cyclin-dependent kinases (CDKs) and casein kinase 2 (CSK2). The biological relevance of the proteome findings was supported by cell proliferation assays using inhibitors of V-ATPase (bafilomycin), CSK2 (CX-4945), CDK4/6 (abemaciclib) and CDK2/7/9 (SNS-032). While bafilomycin preferentially inhibited the cells from relapse patients, the kinase inhibitors were less efficient in these cells. This suggests that therapy against the upregulated kinases could also target the factors inducing their upregulation rather than their activity. This study, therefore, presents markers that could help predict AML relapse and direct therapeutic strategies.

Indexed as

acute myeloid leukemiakinasemarkersmass spectrometrypatient relapsephosphoproteomeproteomeV-ATPase

Identifiers

PMID32192169
PMCPMC7140113
OpenAlexW3012461870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.